Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (191-200 of 201) with videos related to

Pageof 21
Sort By:
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 20, 2021
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendationEric Legius, Ludwine Messiaen, Pierre Wolkenstein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 8, 2022
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationScott R Plotkin, Ludwine Messiaen, Eric Legius, et al.
American Journal of Medical Genetics. Part A|March 26, 2019
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeuticsKatherine A Rauen, Abeer Alsaegh, Shay Ben-Shachar, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
JCO Precision Oncology|September 14, 2020
Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent GlioblastomaAndrew S Chi, Daniel P Cahill, David A Reardon, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 21

Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 20, 2021
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendationEric Legius, Ludwine Messiaen, Pierre Wolkenstein, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 8, 2022
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendationScott R Plotkin, Ludwine Messiaen, Eric Legius, et al.
American Journal of Medical Genetics. Part A|March 26, 2019
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeuticsKatherine A Rauen, Abeer Alsaegh, Shay Ben-Shachar, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
JCO Precision Oncology|September 14, 2020
Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent GlioblastomaAndrew S Chi, Daniel P Cahill, David A Reardon, et al.
American Journal of Medical Genetics. Part A|September 27, 2014
Update from the 2013 International Neurofibromatosis ConferenceScott R Plotkin, Anne C Albers, Dusica Babovic-Vuksanovic, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Neuro-Oncology|June 28, 2025
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cellsRishab Ramapriyan, Fred G Barker, Leland G Richardson, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 21